Receptor Characteristics of the Second Tumor in Synchronous versus Metachronous Breast Cancer

2008 ◽  
Vol 74 (8) ◽  
pp. 702-706 ◽  
Author(s):  
Hanadi Bu-Ali ◽  
Melhem Solh ◽  
Arthi Kapur ◽  
Vijay Mittal
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Histologic Subtype ◽  
Receptor Status ◽  
Number Of Patients ◽  
Metachronous Breast Cancer ◽  
Synchronous Breast Cancer ◽  
Second Tumor

Presently, there is no consensus on whether synchronous breast cancer has the same disease origin as the primary tumor, or if it is a completely independent second primary. This study explores this concept in both synchronous and metachronous breast cancer looking specifically at their receptor characteristics and level of differentiation. A retrospective chart analysis of 114 patients with synchronous or metachronous breast cancer treated at a single institution between January 1991 and March 2004 was done. Sixty-three per cent of the patients were diagnosed with metachronous breast cancer. Synchronous breast cancer was histologically more aggressive ( P < 0.05) with a significantly higher number of patients having poorly differentiated tumors, a greater number of metastases involving a larger number of organs ( P < 0.05), and lower average survival compared with the metachronous group ( P < 0.005). Both the first and second tumor in both groups were similar in hormone receptor status, histologic subtype, and grade. Synchronous breast cancer is more aggressive and has a poorer outcome than metachronous breast cancer. Concordance in hormone receptor status, grade, and histologic subtype between different tumors within the same patient suggests, but does not completely support, a monoclonal origin. Analysis applied here is crude and more specific methods of analysis such as DNA microarray would be required to infer such a conclusion.

Alcohol and breast cancer risk in postmenopausal women: The PLCO experience.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1521-1521
Author(s):  
Roni Falk ◽  
Paige Maas ◽  
Catherine Schairer ◽  
Saundra S. Buys ◽  
Nilanjan Chatterjee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Alcohol Consumption ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Cox Proportional Hazards Model ◽  
Moderate Alcohol Consumption ◽  
Histologic Subtype ◽  
Receptor Status ◽  
Lobular Cancer ◽  
Histologic Subtypes

1521 Background: Moderate alcohol consumption is an established breast cancer (BC) risk factor. Invasive BC is a heterogeneous disease comprised of several histological subtypes with distinct biological features that suggest etiologic differences. Several studies show the alcohol link may be stronger for estrogen receptor-positive tumors (ER+/PR+ and ER+/PR-) and for lobular BC. Few have evaluated the role of alcohol consumption by BC histology and hormone receptor status combined. Methods: We evaluated the risk of BC by baseline alcohol consumption in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial cohort (54649 participants, 1786 incident invasive breast cancers) by histology and hormone receptor status. Histologic subtype-specific associations were evaluated using a recently developed Cox proportional hazards model to calculate multivariate hazards ratios (HR) and 95% confidence intervals (CI). Results: 1444 ductal (81%), 233 lobular (13%) and 109 mixed ductal lobular (6%) cases were identified. The majority were ER+/PR+ (ductal: 959 ER+/PR+, 136 ER+/PR-, 229 ER-/PR-; lobular: 179 ER+/PR+, 37 ER+/PR-, 6 ER-/PR-; mixed ductal/lobular: 88 ER+/PR+, 6 ER+/PR-, 5 ER-/PR-). For ductal and lobular BC, risks for alcohol consumption were modestly elevated; compared to never drinkers, women consuming 7-14 drinks/week had a 40% increase in HR in both histologic subtypes. Risks for mixed ductal lobular cancer were significantly higher, particularly for women consuming 7-14 drinks per week (HR=3.0; 95% CI=1.5, 6.1). For all histologies combined, alcohol risks were confined to ER+/PR+ cancers with HR=1. 6 (95% CI=1.3, 2.1) for women consuming 7-14 drinks/ week; p trend=0.0005. Similarly, for each histologic subtype, the risk for alcohol consumption was limited to ER+/PR+ tumors, and notably, very few cases with pure lobular or mixed ductal lobular cancer were either ER+/PR- or ER-/PR-. Conclusions: Moderate alcohol consumption is associated with risk of ER+/PR+ BC in each of the predominant histologic subtypes, but not with hormone receptor-negative cancer. Unlike other studies, we did not find a link between alcohol consumption and ER+/PR- BC.

scholarly journals Second Primary Breast Cancer Occurrence According to Hormone Receptor Status

2009 ◽  
Vol 101 (15) ◽  
pp. 1058-1065 ◽  
Author(s):  
A. W. Kurian ◽  
L. A. McClure ◽  
E. M. John ◽  
P. L. Horn-Ross ◽  
J. M. Ford ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Receptor Status ◽  
Cancer Occurrence

scholarly journals Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Matteo Lambertini ◽  
Marcello Ceppi ◽  
Anne-Sophie Hamy ◽  
Olivier Caron ◽  
Philip D. Poorvu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Young Patients ◽  
Disease Free Survival ◽  
Distant Recurrence ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Clinical Behavior ◽  
Receptor Status ◽  
The Impact

AbstractYoung breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [HR−]) on clinical behavior and outcomes of mBRCA BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included mBRCA patients diagnosed, between January 2000 and December 2012, with stage I–III invasive early BC at age ≤40 years. From 30 centers worldwide, 1236 young mBRCA BC patients were included. Among 808 and 428 patients with mBRCA1 or mBRCA2, 191 (23.6%) and 356 (83.2%) had HR+tumors, respectively (P < 0.001). Median follow-up was 7.9 years. Second primary BC (P = 0.009) and non-BC malignancies (P = 0.02) were more frequent among mBRCA1 patients while distant recurrences were less frequent (P = 0.02). Irrespective of hormone receptor status, mBRCA1 patients had worse disease-free survival (DFS; adjusted HR = 0.76, 95% CI = 0.60–0.96), with no difference in distant recurrence-free interval (DRFI) and overall survival (OS). Patients with HR+ disease had more frequent distant recurrences (P < 0.001) and less frequent second primary malignancies (BC: P = 0.005; non-BC: P = 0.18). No differences in DFS and OS were observed according to hormone receptor status, with a tendency for worse DRFI (adjusted HR = 1.39, 95% CI = 0.94–2.05) in patients with HR+ BC. Type of mBRCA gene and hormone receptor status strongly impact BC clinical behavior and outcomes in mBRCA young patients. These results provide important information for patients’ counseling on treatment, prevention, and surveillance strategies.

scholarly journals Comparison of Grading and ER, PR Hormone Receptor Status of Carcinoma Breast in FNAC with Histopathology - A Cross Sectional Study from Thrissur, Kerala

2021 ◽  
Vol 8 (21) ◽  
pp. 1696-1700
Author(s):  
Suma Madathiveetil ◽  
Jisha Kalathil Thodiyil ◽  
Freena Rose
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Cross Sectional Study ◽  
Hormone Receptor Status ◽  
Sectional Study ◽  
Cross Sectional ◽  
Carcinoma Breast ◽  
Receptor Status ◽  
Common Cancer ◽  
Number Of Patients

BACKGROUND Breast cancer is now the most common cancer in cities in India and 2 nd most common cancer in the rural areas. Fine needle aspiration cytology (FNAC) is a less invasive pre-operative diagnostic method and is preferred over core / excision biopsy to decide the benign or malignant nature of the breast lump. Prognostic factor assessment by FNAC would allow the identification of patients who would benefit from neo adjuvant treatment (patients with grade 3 tumours) and in whom conservation surgery is inadvisable.1 The purpose of this study is to compare the grades of breast cancer in FNAC with histopathology as gold standard and compare the oestrogen (ER) and progesterone (PR) hormonal expression pattern on immunocytochemistry (ICC) with immunohistochemistry (IHC). From this study we intend to assess the usefulness of cytological grading and ER, PR hormone receptor status pre-operatively so that hormonal therapy can be included with neoadjuvant chemotherapy. METHODS This is a cross sectional study with a sample size of 50, conducted in the Department of Pathology. RESULTS Out of 50 cases, maximum number of patients were in the age group of 51 - 60 years. 68 % had attained menopause; 69 % of patients had tumour size between 2 - 5 cm and 90 % of tumours were in the upper outer quadrant of breast. Considering hormonal expression, in case of ER there was a moderate agreement between ICC and IHC (κ = .428, P = 0.005) and no agreement was seen in case of PR (κ = .073, P = 0.625). Regarding the cytological grading, this study showed highest degree of concordance with grade II tumours with a sensitivity of 75.9 %. For Grade I it was 2.5 % and for grade III, it was 33.3 %. CONCLUSIONS Evaluation of hormonal status and nuclear grading is fairly reliable on cytology when performed on qualitatively superior FNAC material from the primary breast lesions. KEYWORDS Carcinoma Breast, FNAC, ER / PR, Immunocytochemistry, Immunohistochemistry, Cytological Nuclear Grading

scholarly journals Risk of contralateral second primary breast cancer according to hormone receptor status in Germany

2014 ◽  
Vol 16 (5) ◽  
Author(s):  
Carsten Rusner ◽  
Katharina Wolf ◽  
Ulrike Bandemer-Greulich ◽  
Jutta Engel ◽  
Christa Stegmaier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Receptor Status

Hormone receptor status in primary breast cancer—time for a consensus?

2002 ◽  
Vol 38 (9) ◽  
pp. 1201-1203 ◽  
Author(s):  
G.C Wishart ◽  
M Gaston ◽  
A.A Poultsidis ◽  
A.D Purushotham
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Receptor Status

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

2021 ◽  
pp. 41-44
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Histological Grade ◽  
Systemic Disease ◽  
Lymph Node Involvement ◽  
Hormone Receptor Status ◽  
Major Health Problem ◽  
Receptor Status ◽  
Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

scholarly journals Is the biology of breast cancer changing? A study of hormone receptor status 1984–86 and 1996–1997

2008 ◽  
Vol 34 (10) ◽  
pp. 1172
Author(s):  
Sylvia Brown ◽  
E. Mallon ◽  
J. Edwards ◽  
F. Campbell ◽  
L. McGlynn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status
Sign in / Sign up

Export Citation Format

Share Document